Publications
Filters: First Letter Of Title is N [Clear All Filters]
“No evidence that chloroquine or hydroxychloroquine induce hemolysis in G6PD deficiency”, Blood Cells, Molecules & Diseases, vol. 85, pp. 102484-102484, 2020.
, “The natural course of a localized BCG vaccine abscess”, Vaccine, vol. 37, no. 20, p. 2757, 2019.
, “New malaria maps”, Lancet, vol. 394, no. 10195, pp. 278-279, 2019.
, “"Nine Dimensions": A multidisciplinary approach for community engagement in a complex postwar border region as part of the targeted malaria elimination in Karen/Kayin State, Myanmar [version 2; peer review: 2 approved]”, Wellcome Open Research, vol. 3, no. 116, p. 116, 2019.
, “Novel differential linear B-cell epitopes to identify Zika and dengue virus infections in patients”, Clin Transl Immunology, vol. 8, no. 7, p. e1066, 2019.
, “Nutrition in transition: historical cohort analysis summarising trends in under- and over-nutrition among pregnant women in a marginalised population along the Thailand-Myanmar border from 1986 to 2016”, Br J Nutr, vol. 121, no. 12, pp. 1413-1423, 2019.
, “A new highly sensitive enzyme-linked immunosorbent assay for the detection of Plasmodium falciparum histidine-rich protein 2 in whole blood”, Malar J, vol. 17, no. 1, p. 403, 2018.
, “"Nine Dimensions": A multidisciplinary approach for community engagement in a complex postwar border region as part of the targeted malaria elimination in Karen/Kayin State, Myanmar”, Wellcome Open Res, vol. 3, p. 116, 2018.
, ““Nine Dimensions”: A multidisciplinary approach for community engagement in a complex postwar border region as part of the targeted malaria elimination in Karen/Kayin State, Myanmar”, Wellcome Open Research, vol. 3, 2018.
, “A novel field-based molecular assay to detect validated artemisinin-resistant k13 mutants”, Malar J, vol. 17, no. 1. p. 175, 2018.
, “Neonatal Hyperbilirubinemia in a Marginalized Population on the Thai-Myanmar Border: a study protocol”, BMC Pediatr, vol. 17, no. 1, p. 32, 2017.
, “Neutralizing Antibodies against Plasmodium falciparum Associated with Successful Cure after Drug Therapy”, PLoS One, vol. 11, no. 7, p. e0159347, 2016.
, “New insights into the Plasmodium vivax transcriptome using RNA-Seq”, Sci Rep, vol. 6, p. 20498, 2016.
, “A new Plasmodium vivax reference sequence with improved assembly of the subtelomeres reveals an abundance of pir genes”, Wellcome Open Res, vol. 1, p. 4, 2016.
, “Numerical Distributions of Parasite Densities During Asymptomatic Malaria”, J Infect Dis, vol. 213, no. 8, pp. 1322-9, 2016.
, “Neonatal intensive care in a karen refugee camp: a 4 year descriptive study”, PLoS ONE, vol. 8, no. 8, p. e72721, 2013.
, “Nonlinear mixed-effects modelling of in vitro drug susceptibility and molecular correlates of multidrug resistant Plasmodium falciparum”, PLoS ONE, vol. 8, no. 7, p. e69505, 2013.
, “New insights into acquisition, boosting and longevity of immunity to malaria in pregnant women”, J Infect Dis, 2012.
, “No Association of Phenotypic ABO Blood Group and Malaria during Pregnancy”, Am J Trop Med Hyg, vol. 87, no. 3, pp. 447-9, 2012.
, “Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance”, PLoS ONE, vol. 6, no. 5, p. e20212, 2011.
, “A novel histological grading scheme for placental malaria applied in areas of high and low malaria transmission”, J Infect Dis, vol. 202, no. 10, pp. 1608-16, 2010.
, ,
“New Medicines for Tropical Diseases in Pregnancy: Catch-22”, PLoS Medicine, vol. 5, no. 6, p. e133, 2008.
, “No Evidence of Cardiotoxicity of Atovaquone-Proguanil Alone or in Combination with Artesunate”, Am J Trop Med Hyg, vol. 73, no. 2, pp. 267-268, 2005.
, “A new approach for neurological evaluation of infants in resource-poor settings”, Annals of Tropical Paediatrics, vol. 22, no. 4, pp. 355-68., 2002.
, “Neonatal neurological testing in resource-poor settings”, Annals of Tropical Paediatrics, vol. 20, no. 4, pp. 323-36., 2000.
, “Naturally acquired immunity to vivax malaria”, Lancet, vol. 354, p. 162, 1999.
, “Neuropsychiatric Adverse Effects of Mefloquine: What Do We Know and What Should We Do?”, CNS DRUGS, vol. 11, no. 1, pp. 1-8, 1999.
, “No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine”, American Journal of Tropical Medicine and Hygiene, vol. 61, no. 6, pp. 964-7, 1999.
, “New antimalarials. A risk-benefit analysis”, DRUG SAFETY, vol. 12, no. 4, pp. 264-73, 1995.
, “Non specific resistance against malaria pre-erythrocytic stages: involvement of acute phase proteins”, Parasite, vol. 2, no. 3, pp. 263-8, 1995.
,